ArticleGeroScience2026
Early-life exposures, biological age acceleration, and type 2 diabetes in adulthood: mediation analyses in the UK Biobank.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early-life exposures could affect the risk of type 2 diabetes (T2D) in adulthood, but the mechanisms remain unclear. We included 319,951 (54.5% women) UK Biobank participants free of T2D at baseline and within the first year of follow-up to investigate whether early-life exposures contribute to T2D through biological aging estimated using the Klemera-Doubal (KDM) and PhenoAge methods. We first examined associations of exposures with biological age and T2D, respectively, using multivariable-adjusted linear models and Cox regression models. Next, we investigated the role of biological age acceleration in exposure-T2D associations using mediation analyses. Overall, the mean (standard deviation) chronological age of participants was 56.3 (8.1) years, KDM age was 40.9 (13.1) years, and PhenoAge was 44.4 (10.0) years. 17,062 T2D cases developed during a median (interquartile range) follow-up of 14.3 (13.5-15.0) years. Maternal smoking around birth, being part of a multiple birth, earlier puberty, and being relatively plumper or thinner at age ten were associated with both a higher biological age and T2D risk, while having a higher birth weight and being breastfed were associated with a lower T2D risk. Biological age acceleration partly mediated the exposure-T2D associations, ranging from a proportion of 8.3% (95%CI: 6.0-13.1%) of the association between birthweight-T2D being mediated by PhenoAge to a proportion of 27.7% (95%CI: 15.3-48.5%) of the association between breastfeeding-T2D being mediated by KDM. In conclusion, early-life exposures were associated with biological age acceleration that partly mediated the exposure-T2D associations, highlighting the importance of addressing early-life risks and biological aging in prevention strategies.
Indexed as
Identifiers
41653249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.